Johnson & Johnson’s one-shot vaccine is allowing states to rethink distribution, even as health officials and experts worry some will view it as inferior.
As President Biden accelerates plans for manufacturing vaccines and several states move to reopen, we check in on the virus.
The pharmaceutical giant Merck & Co. agreed to help manufacture Johnson & Johnson’s coronavirus vaccine, in a deal partly brokered by the White House.
The more people who become immune to the virus, the less this scourge will be able to mutate and evade the vaccines already available.
The authorization of a third Covid-19 vaccine will bring millions more doses within days. But health officials worry that some people will see the vaccine as the inferior choice.
But does it work?
A little less than three years ago at the Computer Science Museum in Mountain View, Calif. the founders of a young company hailing from Cambridge, England addressed a crowd of celebrities, investors and entrepreneurs at Y Combinator’s August Demo Day promising a revolution in food science.
Over the years, the event has become a relatively low-tech, low-budget showcase for a group of tech investors and billionaire industry insiders to take a look at early stage businesses that could be their next billion-dollar opportunity.
Sharing the stage with other innovation-minded budding entrepreneurs the Cambridge scientists boasted of a technology could produce a sweetener that would mimic not just the taste of sugar, but the caramelization and stickiness that makes sugar the go-to additive for the bulk of roughly 74% of packaged foods that are made with some form of sweetener. Their company, Cambridge Glycoscience could claim a huge slice of a market worth at least a $100 billion market, they said.
Now, the company has a new name, Supplant, and $24 million in venture capital financing to start commercializing its low-cost sugar substitute made from the waste materials of other plants.
The bitter history of the sweetest ingredient
Sugar came into the human diet roughly 10,000 years ago as sugarcane, which is native to New Guinea and parts of Taiwan and China. Over the next 2,000 years the crop spread from those regions to Madagascar and eventually took root in India, where it was first refined in about 500 BC.
From there, the sweetener spread across the known world. By the first century AD Greek and Roman scholars were referencing its medicinal properties and, after the Crusades, sugar consumption traveled across Europe through the Middle Ages.
It was a welcome replacement from Europe’s mainstay, honey, and the early artificial sweeteners used by the Romans, which contained near-lethal doses of lead.
The cold climates of Northern Europe proved mostly inhospitable to sugarcane cultivation so the root took root in the more temperate South and the islands off of Europe’s southern coast.
Those regions also became home to the first European experiments with agricultural slavery — a byproduct of the sugar trade, and one that would plant the seeds for the international exploitation of indigenous American and African labor for centuries as the industrial growth of sugar production spread to the New World.
First, European indentured servants and enslaved indigenous people’s powered the production of sugar in the Americas. But as native populations died off due to the introduction of European diseases, genocidal attacks, and back-breaking labor, African slaves were brought to the new colonies to work the fields and mills to make refined sugar.
The horrors of slavery may be the most damning legacy of industrial sugar, but it’s far from the only problem caused by the human craving for sweeteners.
As climate change becomes more of a threat, fears of increasing deforestation to meet the world’s demand — or to provide cover for other industrialization of virgin forests — have arisen thanks to new policies in Brazil.
“Conventional cane sugar is heavily heavily water intensive,” said Supplant co-founder Tom Simmons in an interview. That’s another problem for the environment as water becomes the next resource to be stressed by the currents of climate change. And species extinction presents another huge problem too.
“The WWF number one source for biodiversity lost globally is cane sugar plantations,” Simmons said. “Sugar is a massive consumer of water and in contrast, there’s big sustainability pitch for what we do.. the raw materials are products of the current agricultural industry.”
And the quest for sugar substitutes in the U.S. has come with related health costs as high fructose corn syrup has made its way into tons of American products. Invented in 1957, corn syrup is one of the most common sweeteners used to replace sugar — and one that’s thought to have incredibly disastrous effects on the health of consumers worldwide.
The use of corn syrup has been linked to an increasing prevalence of diabetes, obesity, and fatty liver disease, in the world’s population.
Looking For A Healthier Substitute
As Supplant and its investors look to take the crown as the reigning replacement for sugar, they join a long line of would-be occupants to sugar’s throne.
The first viable, non-toxic chemically derived sugar substitute was discovered in the late 18th century by a German chemist. Called saccharine it was popularized initially during sugar shortages caused by the first World War and gained traction during the health crazes of the sixties and seventies.
Saccharin, still available in pink Sweet n’ Low packets and a host of products, was succeeded by aspartame (known commercially as Equal and present as the sugar substitute in beverages like Diet Coke), which was supplanted by sucralose (known as Splenda).
These chemically derived sweeteners have been the standard on the market for decades now, but with a growing push for natural — rather than chemical — substitutes for sugar and their failures to act as a replacement for all of the things that sugar can do as a food ingredient, the demand for a better sugar has never been higher.
Supplanting the competition
“Not everything that we back is going to change the world. This, at scale, does that.” said Aydin Senkut, the founder and managing partner of Felicis Ventures, the venture firm that’s one of Supplant’s biggest backers.
Part of what convinced Senkut is the fact that Supplant’s sweetener has already received preliminary approvals in the European Union by the region’s regulatory equivalent of the Food and Drug Administration. That approval not only covers the sale of Supplant’s product as a sweetener, but also as a probiotic with tangible health benefits he said.
So not only is the Supplant product arguably a better and more direct sugar replacement, as the founders claim, it also has health benefits through providing increased fiber in consumers who use it regularly, Senkut said.
“The European FDA is even stricter than the U.S. FDA,” Senkut said. “[And] they got pre-approval for this.”
Senkut and Felicis invested in Cambridge Glycosciences almost immediately after seeing the company’s presentation at Y Combinator.
“We became the largest investors at seed,” Senkut said.
Its selling points were the products extremely low glycemic index and its ability to be manufactured from waste plant fibers, which means that it ultimately can be produced at a lower cost, according to Senkut.
What’s the difference?
Supplant differs from its competition in a number of other key ways, according to company co-founder Tom Simmons.
While companies like the Israeli startup DouxMatok or Colorado’s MycoTechnology and Wisconsin’s Sensient work on developing additives from fungus or tree roots or bark that can enhance the sweetness of sugars, Supplant uses alternative sugars to create its sweetener, Simmons said.
“The core difference is they’re working with cane sugar,” according to Simmons. “Our pitch is we make sugars from fiber so you don’t need to use cane sugar.”
Simmons said that these other startups have been approaching the problem from the wrong direction. “The problem that their technology addresses isn’t the problem the industry has,” Simmons said. “It’s about texture, bulking, caramelization and crystallization… We have a technology that’s going to give you the same sweetness gram for gram.”
There are six different types of calorific sugar, Simmons explained. There’s lactose, which is the sugar in milk; sucrose, which comes from sugarcane and sugar beets; maltose, found in grains like wheat and barley; fructose, the sugar in fruits and honey; glucose, which is in nearly everything, but especially carbohydrate-laden vegetables, fruits, and grains; and galactose, a simple sugar that derives from the breakdown of lactose.
Simmons said that his company’s sugar substitute isn’t based on one compound, but is derived from a range of things that come from fiber. The use of fibers means that the body recognizes the compounds as fibrous and treats them the same way in the digestive tract, but the products taste and act like sugar in food, he said. “Fiber derived sugars are in the category of sugars, but are not the calorific sugars,” said Simmons.
Trust the process?
Supplant’s technology uses enzymes to break down and fragment various fibers. “As you start breaking it down, it starts looking molecularly like sucrose — like cane sugar — so it starts behaving in a similar way,” said Simmons.
This is all the result of years of research that Simmons began at Cambridge University, he said. “I arrived at Cambridge intending to be a professor. I did not arrive in Cambridge intending to start a business. I was interested in doing science, making inventions and stuff that would reach the wider world. I always imagined the right way for me to do that was to be a professor.”
In time, after receiving his doctorate and beginning his post-doctoral work into the research that would eventually turn into Supplant, Simmons realized that he had to start a company. “To try and do something impactful I was going to have leave the university,” he said.
In some ways, Supplant operates at the intersection of all of Simmons’ interests in health, nutrition, and sustainability. And he said the company has plans to apply the processing technology across a range of consumer products eventually, but for now the company remains focused on the $100 billion sugar substitute market.
“There’s a handful of different core underlying scientific approaches in different spaces,” he said. The sort of things that go into personal care and homecare. Those chemicals. A big drive in the industry is for both less harsh and harsh chemicals in shampoos but also to do so in a way that’s sustainable. That’s made form a sustainable source but also biodegradable.”
With the money that the company has now raised from investors including Bonfire Ventures, Khosla Ventures, Felicis, Soma Capital, and Y Combinator, Supplant is now going to prove its products in a few very targeted test runs.* The first is a big launch with a celebrity chef, which Simmons teased, but did not elaborate on.
Senkut said that the company’s roll out would be similar to the ways in which Impossible Foods went to market. Beginning with a few trial runs in higher end restaurants and foodstuffs before trying to make a run at a mass consumer market.
The feedstocks for Supplant’s sugar substitute come from sugar cane bagasse, wheat and rice husks, and the processing equipment comes from the brewing industry. That’s going to be a benefit as the company looks to build out an office in the U.S. as it establishes a foothold for a larger manufacturing presence down the line.
“We’re taking known science and applying it in the food industry where we know that it has value,” Simmons said. “We’re not inventing any brand new enzymes and each part of the process — none of it on their own are new. The discovery that these sugars work well and can replace cane sugar. That’s someone that no one has done before. Most sugars don’t behave like cane sugar in food. They’re too dry, they’re too wet, they’re too hard, they’re too soft.”
Ultimately the consumer products mission resonates highly for Simmons and his twenty person team. “We’re going to use these hugely abundant renewable resources produced all around the world,” he said.
*This story was updated to include Bonfire Ventures and Khosla Ventures as investors in Supplant.
F.D.A. studies show the shot strongly protects against severe illness and may reduce spread of the virus. But the drugmaker has fallen short of initial production goals.
One activist is asking the Biden administration to remember the failures that led to the opioid epidemic as it chooses the next head of the F.D.A.
The agency’s new guidance will speed the development of vaccines that protect against more contagious variants of the coronavirus.
Two leading contenders generate wider debate about the leadership needed to restore morale and scientific integrity to an agency battered by the politicized Trump administration.
The move comes nearly four years after a study showed that chemicals believed to cause health problems in children and reproductive issues in adults were found in mass-market macaroni and cheese packets.
How soon life returns to normal depends on what we do now.
Federal regulators are in favor of a simple, potentially quick fix to bolster coronavirus vaccine supplies: more doses per bottle.
For now, the government has been relying on a patchwork of programs that officials say are hampered by limited size and gaps in data collection.
When hospitalized with the coronavirus in October, his blood oxygen levels had plunged and officials feared he was on the verge of being placed on a ventilator.
Health workers are still being forced to ration protective masks, but small U.S. manufacturers can’t find buyers, and some are in a danger of going under.
A link to the vaccines is not certain, and investigations are underway in some reported cases.
Disinformation has pervaded social media and is an assault on our people.
How Zeynep Tufekci saw Covid-19 coming, and what she thinks we’re still getting wrong.
Practical pandemic guidance is still a huge problem.
Forget boosters and more trials. America’s overly prudent vaccination strategy is killing people.
“Let’s not wait until we wrap the car around the tree to start pumping the brakes.”
President Biden said the amount of coronavirus vaccines reaching the states would rise next week and a deal was near to provide enough shots to vaccinate nearly all Americans by the end of summer.
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
The Biden administration has yet to name a permanent chief of the Food and Drug Administration, amid a deep review of potential treatments and vaccines against the coronavirus.
The Trump administration wants to mandate job reviews for top government scientists and managers every five years, which could lead to reassignment.
Dr. David Kessler, who helped speed the development and approval of AIDS drugs in the 1990s, will become the top science official at Operation Warp Speed.
Midwestern Pet Foods Inc. expanded a voluntary recall after fatal levels of a toxin produced by mold were found in some of its products, the F.D.A. said.
Brazil says CoronaVac has an efficacy rate just over 50 percent, much lower than previously announced. More than 380 million doses have already been ordered.
Should second doses be delayed? Should most adults receive half-doses? Scientists are pondering ways to get more shots into more arms.
Midwestern Pet Foods Inc. issued the voluntary recall after tests showed that aflatoxin, which is produced by mold, exceeded acceptable levels, the F.D.A. said.
As the U.S. confronted a new wave of infection and death through the summer and fall, the president’s approach to the pandemic came down to a single question: What would it mean for him?
Midwestern Pet Foods Inc. issued the voluntary recall after tests showed that aflatoxin, which is produced by mold, exceeded acceptable levels, the F.D.A. said.
Here’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.
A newly identified variant of the SARS-CoV-2 virus appears to be more contagious than established ones. Here’s what scientists know.
The federal agency said it was seeking to revoke its definition for the carrot-colored dressing, effectively erasing a government-required list of ingredients at the request of an industry group.
The Food and Drug Administration authorized a second coronavirus vaccine for emergency use, clearing the way for millions more Americans to be immunized next week.
A deep distrust of the government is fueling vaccine hesitancy among Republicans, who are more likely than Democrats to resist being inoculated against Covid-19.
Data suggests significant protection even without a second shot. If studies prove that’s true, it could be a game changer.
An advisory group’s recommendation will mean millions more Americans can be inoculated, extending protection against Covid beyond major urban areas into rural and suburban regions.
Pharmacists have found that they can squeeze an additional dose from some of the glass vials that were supposed to contain five doses of the Pfizer vaccine.
The test seems likely to improve the diagnosis and treatment of a disease that kills 33,000 American men each year.
Walgreens and CVS staff will soon begin vaccinations at tens of thousands of long-term care facilities. Some staff and residents are wary, and there are thorny issues of consent.
The positive review likely ensures that the F.D.A. will grant emergency authorization for a second coronavirus vaccine this week for millions of Americans.
The vital medical devices could be inexpensive and available over the counter. But efforts have stalled under the F.D.A.
Vaccinations are scheduled to take place on Monday, according to one hospital system.
An initial shipment of about 2.9 million doses of Pfizer’s coronavirus vaccine will be sent around the United States over the next week. So what happens next?
The first of nearly three million doses were sent across the country, the start of the most ambitious vaccination campaign in the nation’s history.
Although no coronavirus vaccine has been studied in these women, many scientists believe the benefits will outweigh any potential risks.